The global leader in cancer deaths is often preventable

Science · Published 24 October 2026 Swipe more like this →

In short: Lung cancer remains a staggering public health challenge, accounting for the highest number of cancer deaths worldwide. While it is frequently associated with smoking, the mechanisms of its development and the diversity of its types create a complex landscape for diagnosis and treatment.

Global mortality from cancer peaked with lung disease in 2022, involving roughly 1.8 million fatalities and 2.5 million new diagnoses. A significant portion of these cases—over 1.3 million in men and nearly 500,000 in women—are considered preventable. While tobacco smoking remains the primary driver, accounting for 60–70% of cases, other critical risk factors include air pollution, radon exposure, and occupational hazards like asbestos, silica, and diesel exhaust. Secondhand smoke also contributes to the risk profile for many individuals. Public health efforts focus on smoke-free environments and tobacco control policies. These primary prevention measures aim to reduce the initial occurrence of the disease.

The disease manifests primarily through the uncontrolled growth of abnormal cells triggered by carcinogens. These cells multiply to form tumors that destroy lung tissue and can metastasize to the liver, bones, adrenal glands, and brain. Medical professionals divide the illness into two primary categories by microscopic look: non-small cell lung cancer (NSCLC), making up about 85% of instances, and the rarer, usually more virulent small cell lung cancer (SCLC). The growth of these tumors eventually destroys the surrounding lung areas. Genetic susceptibility also plays a role in how the disease develops. Certain chronic lung diseases can further increase a person's vulnerability.

Treatment strategies vary significantly based on these types and the stage of the disease. NSCLC is more likely to be localized at diagnosis and may be treatable with surgery, though it often responds poorly to standard chemotherapy. In contrast, SCLC is rarely localized even when detected early and is seldom treated with surgery. Because early symptoms like persistent cough or fatigue are often dismissed as minor issues, screening high-risk individuals is a primary focus for improving survival rates. Advanced genetic testing can now help predict how specific patients might react to targeted therapies. Patients may also experience recurring infections in the lungs. Diagnosis programs are essential to minimize delays in care after symptoms first appear.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Lung cancer led world cancer deaths with 1.8 million in 2020
• Tobacco smoking is the world’s top preventable killer
• Why lung cancer remains a leading cause of death worldwide
• Why lung cancer remains one of the world's deadliest diseases
• The metrics that define how well you breathe
• Can we harness the therapeutic power of psychedelics without the hallucinogenic trip?
• The delicate double-layered membrane that enables every breath you take
• The human footprint on our planet's variety of life
• When do humans actually learn to lie and grasp the concept of possibility?
• Why biodiversity acts as a biological insurance policy against collapse
• Which operating system actually powers the most efficient AI development?
• Can simple daily habits effectively lower your risk of invasive cancer?

More in Science · Latest · A–Z · All topics